Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-07-18 23:02 | 2025-07-17 | APLS | Apellis Pharmaceuticals Inc. | Francois Cedric | Director, Officer | OPT+S | $20.21 | 19,725 | $398,735 | 331,605 |
| 2025-07-18 23:00 | 2025-07-16 | APLS | Apellis Pharmaceuticals Inc. | Watson David O. | Officer | SELL | $19.55 | 5,000 | $97,750 | 128,730 |
| 2025-07-18 23:07 | 2025-07-17 | ESPR | Esperion Therapeutics, Inc. | Looker Benjamin | Officer | SELL | $1.13 | 1,304 | $1,470 | 399,937 |
| 2025-07-18 23:05 | 2025-07-17 | ESPR | Esperion Therapeutics, Inc. | Halladay Benjamin | Officer | SELL | $1.12 | 11 | $12 | 474,462 |
| 2025-07-18 23:30 | 2025-07-16 | SNDX | Syndax Pharmaceuticals Inc | Goldan Keith A. | Officer | SELL | $9.29 | 1,296 | $12,033 | 92,450 |
| 2025-07-18 23:30 | 2025-07-16 | SNDX | Syndax Pharmaceuticals Inc | Metzger Michael A | Director, Officer | SELL | $9.29 | 7,534 | $69,953 | 298,661 |
| 2025-07-18 21:42 | 2025-07-18 | CALC | CalciMedica, Inc. | WILSON ROBERT N | Director | BUY | $2.87 | 4,500 | $12,915 | 422,029 |
| 2025-07-18 23:12 | 2025-07-17 | JNJ | JOHNSON & JOHNSON | REED JOHN C | Officer | SELL | $163.55 | 19,137 | $3,129,830 | 10,658 |
| 2025-07-18 23:13 | 2025-07-16 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | FRIEDMAN PAUL A | Director | OPT+S | $353.19 | 28,876 | $10,198,844 | 187,164 |
| 2025-07-18 23:11 | 2025-07-16 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Taub Rebecca | Director | OPT+S | $353.19 | 29,101 | $10,278,098 | 461,044 |
| 2025-07-18 17:38 | 2025-07-17 | GALT | GALECTIN THERAPEUTICS INC | FREEMAN KEVIN D | Director | BUY | $2.90 | 5,000 | $14,495 | 49,769 |
| 2025-07-17 23:32 | 2025-07-15 | NUVL | Nuvalent, Inc. | Balcom Alexandra | Officer | OPT+S | $84.67 | 20,000 | $1,693,496 | 61,734 |
| 2025-07-17 23:31 | 2025-07-15 | NUVL | Nuvalent, Inc. | Porter James Richard | Director, Officer | OPT+S | $82.27 | 27,000 | $2,221,420 | 249,062 |
| 2025-07-17 23:15 | 2025-07-15 | CNTA | Centessa Pharmaceuticals plc | HUSSAIN IQBAL J | Officer | OPT+S | $14.93 | 6,000 | $89,567 | 105,386 |
| 2025-07-18 03:51 | 2025-07-16 | MNKD | MANNKIND CORP | Binder Steven B. | Director | SELL | $3.94 | 75,367 | $296,946 | 830,508 |
| 2025-07-18 00:19 | 2025-07-15 | NAMS | NewAmsterdam Pharma Co N.V. | Kling Douglas F | Officer | OPT+S | $21.26 | 98,612 | $2,096,659 | 44,000 |
| 2025-07-17 17:40 | 2025-07-14 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $5.01 | 6,500 | $32,565 | 0 |
| 2025-07-18 03:46 | 2025-07-16 | MNKD | MANNKIND CORP | Thomson David | Officer | SELL | $3.94 | 7,466 | $29,416 | 841,719 |
| 2025-07-18 00:20 | 2025-07-15 | PTCT | PTC THERAPEUTICS, INC. | Gravier Pierre | Officer | SELL | $49.46 | 2,516 | $124,441 | 71,920 |
| 2025-07-16 23:14 | 2025-07-15 | RAPP | Rapport Therapeutics, Inc. | Bredt David | Officer | SELL | $14.00 | 8,500 | $118,962 | 435,142 |
| 2025-07-16 23:30 | 2025-07-14 | KNSA | Kiniksa Pharmaceuticals International, plc | Tessari Eben | Officer | OPT+S | $28.72 | 18,900 | $542,808 | 49,163 |
| 2025-07-17 04:02 | 2025-07-14 | MNPR | Monopar Therapeutics | Robinson Chandler | Director, Officer | SELL | $40.00 | 16,800 | $672,020 | 73,472 |
| 2025-07-17 01:01 | 2025-07-14 | TBPH | Theravance Biopharma, Inc. | Farnum Rhonda | Officer | SELL | $11.39 | 10,000 | $113,870 | 326,918 |
| 2025-07-16 19:58 | 2025-07-14 | CALC | CalciMedica, Inc. | Roberts Eric W | Director, Officer, 10% owner | BUY | $2.43 | 6,500 | $15,810 | 44,323 |
| 2025-07-16 23:20 | 2025-07-14 | ANNX | Annexon, Inc. | Yednock Ted | Officer | SELL | $2.58 | 1,116 | $2,879 | 105,084 |
| 2025-07-16 23:20 | 2025-07-14 | ANNX | Annexon, Inc. | Overdorf Michael | Officer | SELL | $2.61 | 853 | $2,226 | 130,689 |
| 2025-07-16 23:11 | 2025-07-14 | APLS | Apellis Pharmaceuticals Inc. | Francois Cedric | Director, Officer | OPT+S | $20.19 | 139,365 | $2,813,096 | 342,333 |
| 2025-07-16 23:20 | 2025-07-14 | ANNX | Annexon, Inc. | Lew Jennifer | Officer | SELL | $2.58 | 1,117 | $2,882 | 121,616 |
| 2025-07-17 04:06 | 2025-07-14 | MNPR | Monopar Therapeutics | Tsuchimoto Kim R | Director | SELL | $40.00 | 8,904 | $356,171 | 11,486 |
| 2025-07-17 04:03 | 2025-07-14 | MNPR | Monopar Therapeutics | STARR CHRISTOPHER M | Director | SELL | $40.00 | 16,800 | $672,020 | 5,173 |
| 2025-07-15 23:36 | 2025-07-14 | LQDA | Liquidia Corp | Schundler Russell | Officer | OPT+S | $14.28 | 7,836 | $111,898 | 577,977 |
| 2025-07-15 23:36 | 2025-07-14 | LQDA | Liquidia Corp | Saggar Rajeev | Officer | OPT+S | $14.28 | 5,327 | $76,070 | 271,413 |
| 2025-07-15 23:35 | 2025-07-14 | LQDA | Liquidia Corp | Moomaw Scott | Officer | OPT+S | $14.28 | 4,797 | $68,501 | 223,231 |
| 2025-07-15 23:35 | 2025-07-14 | LQDA | Liquidia Corp | Krepp Sarah | Officer | SELL | $14.28 | 2,673 | $38,170 | 142,499 |
| 2025-07-15 23:30 | 2025-07-14 | LQDA | Liquidia Corp | Boyle Dana | Officer | SELL | $14.28 | 1,193 | $17,036 | 187,168 |
| 2025-07-15 23:30 | 2025-07-14 | LQDA | Liquidia Corp | Adair Jason | Officer | OPT+S | $14.28 | 2,576 | $36,785 | 193,634 |
| 2025-07-15 23:34 | 2025-07-14 | LQDA | Liquidia Corp | Kaseta Michael | Officer | OPT+S | $14.28 | 11,580 | $165,362 | 406,412 |
| 2025-07-16 00:01 | 2025-07-11 | MLYS | Mineralys Therapeutics, Inc. | Levy Adam Scott | Officer | SELL | $14.45 | 10,758 | $155,454 | 206,612 |
| 2025-07-16 00:00 | 2025-07-14 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Officer | OPT+S | $14.59 | 11,366 | $165,879 | 97,907 |
| 2025-07-16 00:02 | 2025-07-11 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | Director, Officer | SELL | $14.51 | 15,884 | $230,431 | 846,405 |
| 2025-07-16 03:54 | 2025-07-11 | IONS | IONIS PHARMACEUTICALS INC | Monia Brett P | Director, Officer | SELL | $41.74 | 1,160 | $48,416 | 179,820 |
| 2025-07-15 13:03 | 2025-07-11 | ANIX | Anixa Biosciences Inc. | Titterton Lewis H jr | Director | BUY | $3.14 | 10,000 | $31,400 | 943,334 |
| 2025-07-16 00:11 | 2025-07-14 | DYN | Dyne Therapeutics, Inc. | Cox John | Director, Officer | BUY | $9.11 | 100,000 | $911,000 | 242,179 |
| 2025-07-16 04:29 | 2025-07-14 | CALC | CalciMedica, Inc. | Leheny A. Rachel | Director, Officer, 10% owner | BUY | $2.47 | 2,500 | $6,175 | 2,500 |
| 2025-07-15 23:05 | 2025-07-10 | AGIO | Agios Pharmaceuticals Inc. | Scadden David | Director | OPT+S | $40.00 | 1,400 | $56,000 | 17,603 |
| 2025-07-15 23:33 | 2025-07-14 | LQDA | Liquidia Corp | JEFFS ROGER | Director, Officer | OPT+S | $14.28 | 20,252 | $289,199 | 1,038,560 |
| 2025-07-16 00:53 | 2025-07-15 | INSM | INSMED Inc | Lewis William | Director, Officer | OPT+S | $102.37 | 6,830 | $699,221 | 233,924 |
| 2025-07-16 00:52 | 2025-07-11 | INSM | INSMED Inc | Smith Michael Alexander | Officer | SELL | $99.80 | 1,681 | $167,757 | 66,394 |
| 2025-07-16 00:38 | 2025-07-14 | CYTK | CYTOKINETICS INC | Blum Robert I | Director, Officer | SELL | $38.15 | 5,000 | $190,750 | 393,108 |
| 2025-07-14 23:02 | 2025-07-10 | ARQT | Arcutis Biotherapeutics Inc. | Burnett Patrick | Officer | OPT+S | $15.05 | 28,750 | $432,699 | 115,468 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.